The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
REGULATORY
Xocova to Be Commercially Available from March 31
Shionogi’s COVID-19 pill Xocova (ensitrelvir) will be available under the normal commercial distribution channel in Japan, beginning on March 31, according to the health ministry. Xocova obtained Japan’s first emergency approval in November and has since been allocated under the…
To read the full story
Related Article
- Shionogi’s Xocova Now Available through Normal Commercial Channel
April 3, 2023
- Chuikyo OKs Listing of Mounjaro, Libtayo, Imjudo; 30 Billion-Plus Peak Sales for Lilly Med
March 9, 2023
- Xocova Priced at 51,851 Yen per Course with Peak Sales Put at 19.2 Billion Yen
March 9, 2023
- Chuikyo OKs Pricing Plan for Xocova Listing, 100 Billion Yen Threshold for Possible Re-Pricing
February 16, 2023
- Pharma Trade Groups Stress Concern for Re-Pricing Debate over Xocova: Chuikyo
February 9, 2023
- Chuikyo Talks Over Sales Criteria to Trigger Possible Xocova Re-Pricing; Is 3-Month-Based Estimate an Overestimate?
February 9, 2023
- Chuikyo OKs Use of Multiple Comparators to Price Xocova, Upping of Reduction Cap Mooted for Re-Pricing
February 2, 2023
- Chuikyo Begins Xocova Price Debate under Mega Seller Rule, Weighs Quicker Re-Pricing
January 26, 2023
- Xocova Might Trigger Mega Seller Price Control Rule for First Time
January 24, 2023
REGULATORY
- Japan Panel to Review Pfizer’s Cancer Med Tukysa on January 29
January 16, 2026
- Study Group Calls for Independent Body to Centrally Manage Whole Genome Data
January 16, 2026
- Expert Calls for Full Verification of CEA Guidelines and Analytical Frameworks
January 16, 2026
- Japan Sets New Pricing Rules for Conditionally Approved Regenerative Medicines, Starting with Elevidys
January 15, 2026
- MHLW Orders Label Revisions for Aspirin, CAR-T Therapies, and Other Drugs
January 14, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…